medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2009, Number 3

<< Back Next >>

Rev Esp Med Quir 2009; 14 (3)

Osteoporosis. Basic concepts for daily practice

Guzmán CJ, Flores MR, Gómez MJ, Soberanes GE, Escarela SM, DHyver DC

Language: Spanish
References: 30
Page: 128-140
PDF size: 385.73 Kb.


ABSTRACT

In the United States, it is reported that approximately 6 million women are affected by osteoporosis, with an annual incidence of fractures of approximately 1.2 million, generating an annual expenditure that exceeds 10 billion dollars, calculated that of all patients with fractures, 20% die from complications of the fracture. This process of bone remodelling is controlled by a complex interaction between osteoblast and osteoclastic cells, including multiple cytokines. The system RANK-RANKL-osteoprotegerine is considered these days the common pathway of bone remodelling, system through which hormones and cytokines act both locally and systemic balancing both bone formation and destruction. At present there are several treatment regimens that encourage better adherence to treatment being bisphosphonates drugs in front-line treatment.


REFERENCES

  1. Khosla SM, Melton JL. Osteopenia. N Engl J Med 2007;356:2293-3000.

  2. Riancho JA, Gutiérrez RP. Factores reguladores de la resorción ósea. Rev Metab Oseo Min 2003;(2):51-56.

  3. Montenegro SD, Pedroza NI, Vargas ES. Metabolismo óseo: Actualización. Revista de postgrado de la VI Cátedra de Medicina 2002;117:116-23.

  4. Roig ED, Pérez EL. Documento de consenso 2006 de la Sociedad Española de Reumatología sobre la osteoporosis posmenopáusica. Reumatol Clin 2007;(Supl. 1):26-32.

  5. Physician’s guide to prevention and treatment of osteoporosis. Washington: National.

  6. Francis MR. Enfermedad metabólica ósea. En: Tallis CR, Fillit MH, editores. Brocklehurst’s Geriatría. España: Marban, 2007;pp:871-6.

  7. Boyce BF, Xing L. Biology of RANK, RANKL and osteoprotegerin. Arthritis Res Ther 2007;9(Suppl 1.):S3:1186-2167.

  8. Cons MF. La identificacion de las fracturas vertebrales. Rev Metab Oseo Min 2004;2(1):127-36.

  9. Cons MF. Marcadores bioquímicos de remodelado óseo. Rev Metab Oseo Min 2004;2(1):37-47.

  10. Cons MF. Marcadores bioquímicos de remodelado óseo. Rev Metab Oseo Min 2003;1(3):91-98.

  11. Position Statement: management of osteoporosis in postmenopausal women. 2006 position statement of The North American Menopause Society. Menopause 2006;13(3):340-65.

  12. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:210-8.

  13. Simon LS. Osteoporosis. Rheum Dis Clin North Am 2007;(33):149-76.

  14. Holick FM. Vitamin D deficiency. N Engl J Med 2007;357:266-81.

  15. Raisz LG. Pathogenesis of osteoporosis. Concepts, conflicts and prospects. J Clin Invest 2005;115:3318-25.

  16. Miller PD, Mcclung MR, Macovei L. Monthly oral ibandronate therapy in posmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 2005;20:1315-22.

  17. Delmas PD, Adami S, Strugala C, Stakkestad JA, et al. Intravenous ibandronate injections in posmenopausal women with osteoporosis: one year results from the Dosing Intravenous Administration Study. Arthritis Rheum 2006;54:1838-46.

  18. Bone GH, Hosking D, Devogelaer PJ, Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.

  19. Rose JC. Postmenopausal osteoporosis. N Engl J Med 2005;353:595-603.

  20. Black DM, Delmas PD, Eastell R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.

  21. Lyles KW, Magaziner JS, Adachi JD. Zolendronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1-10.

  22. Black DM, Boones S, Cauley J, Delmas P, et al. Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON privotal fracture trial. J Bone Min Res 2006;21(Suppl.):s16.

  23. Canalis E, Giustina A, Bilezkain P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007;357:905-9.

  24. Hodsman AB, Bauer DC, Dempster DW, Dian L, et al. Parathyroid hormone and teriparatide for treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26(5):688-703.

  25. Yaffe K, Krueger K, Cummings RS. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005;162:683-90.

  26. Gol M, Baris N, Guneri S, Posaci C. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women. J AJOG 2006;194:1249-54.

  27. Reginster JY, Seeman E, De Vernejoul MC. Strountium ranelate reduces the risk of nonvertebral fractures in posmenopausal women with osteoporosis. Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.

  28. Seeman E, Vellas B, Benhamov C. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Boneminer Res 2006;21:1113-20.

  29. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, et al. Denosumab in postmenopausal women with low bone miner density. N Engl J Med 2006;821-34.

  30. McClung M. Role of RANKL inhibition in osteoporosis. Arthritis Res Ther 2007;9(Suppl. 1):S3.




2020     |     www.medigraphic.com